Loading...
Patients with colorectal cancer and peritoneal disease amenable to cytoreductive surgery are often treated with hyperthermic intraperitoneal chemotherapy (HIPEC), based largely on findings from retrospective studies. Advances in systemic therapy leading to improved survival in the past 15 years have made results from older surgical series difficult to interpret. Investigators report results of PRODIGE 7, an open-label, multicenter, randomized phase 3 trial comparing cytoreductive surgery alone with surgery plus HIPEC — intravenous fluorouracil (400 mg/m2) and leucovorin (20 mg/m2) followed by oxaliplatin administered by closed (360 mg/m2) or open (460 mg/m2) abdomen technique over 30 minutes at 43°C. Eligible patients had a peritoneal cance…